{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2019"],"data_sharing_plan":["IPD Sharing (as of July 2019): No"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2310049"],"location":["China"],"study_start_month":["7"],"keyword":["Second line","XELOX","Regorafenib","Oxaliplatin","Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer","description":"This is an interventional, randomized open-label, parallel-group, multicenter, dose escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd line treatment in mCRC patients.","dates":{"creation":"2019-07-15"},"accession":"2310049","cross_references":{"ClinicalTrials___gov":["NCT04008511"]}}